## Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia

## Using Multiparametric Flow Cytometry and Next-Generation Sequencing

Sang Mee Hwang, M.D. ${ }^{1,2}$, Inseong Oh, M.D. ${ }^{2}$, Seok Ryun Kwon, M.D. ${ }^{2}$, Jee-Soo Lee, M.D. ${ }^{2}$, and Moon-Woo Seong, M.D. ${ }^{2}$
${ }^{1}$ Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea; ${ }^{2}$ Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea

## Validation of in-house multiparametric flow cytometric-measurable residual disease (MFC-MRD) assay

The analytical performance was assessed by evaluating accuracy, precision, linearity, limit of detection (LOD) and lower limit of quantitation (LLOQ) based on Clinical and Laboratory Standards Institute H62 guideline with modification [1]. Accuracy was validated by comparison against validated molecular results in 20 samples. The MRD results should reach $\geq 90 \%$ concordance for qualitative results. For precision, low-level samples were tested at least twice and coefficient of variation (CV) should be within $35 \%$. For linearity, leukemic samples and normal samples were mixed and created at least 3 levels and the correlation coefficient $\left(\mathrm{R}^{2}\right)$ $>0.95$. The limit of blank (LOB) and LOD were assessed using three normal samples. Calculation for LOB and LOD were based on the following formulas: $\mathrm{LOB}=$ mean +1.654 SD (standard of deviation), LOD $=$ mean +3 SD. For LLOQ, samples with low level of target population were assessed twice and the MRD events within $35 \%$ CV was selected for LLOQ.

1) Accuracy: Comparison with previously validated tests

The MFC-MRD results of 20 samples with BCR::ABL1, ETV6::RUNX1 RT-PCR results were compared. Out of 20 samples, 1 discordant case was present, within the prespecified acceptance criteria ( $\geq 90 \%$ concordance).

| ID | MFC- <br> MRD | MFC- <br> MRD $(\%)$ | Molecular test results |
| :--- | :--- | :--- | :--- |
| 1 | Negative |  | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |
| 2 | Negative |  | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=0.002$ |
| 3 | Negative | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |  |
| 4 | Positive | 0.0013 | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=0.1$ |
| 5 | Negative | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |  |
| 6 | Negative | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |  |
| 7 | Negative | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |  |


| 8 | Negative |  | $B C R-A B L 1 / A B L 1$ minor \% ratio $=$ Not detected |
| :---: | :---: | :---: | :---: |
| 9 | Negative |  | $B C R-A B L 1 / A B L 1$ minor $\%$ ratio $=$ Not detected |
| 10 | Negative |  |  |
| 11 | Negative |  | $B C R-A B L 1 / A B L 1$ minor \% ratio $=$ Not detected |
| 12 | Positive | 0.0021 | $B C R-A B L 1 / A B L 1$ minor $\%=0.02$ |
| 13 | Negative |  | $B C R-A B L 1 / A B L 1$ minor $\%=0.004$ |
| 14 | Negative |  | $B C R-A B L 1 / A B L 1$ minor \% ratio $=$ Not detected |
| 15 | Negative |  | $B C R-A B L 1 / A B L 1$ minor \% ratio $=$ Not detected |
| 16 | Negative |  | ETV6-RUNX1/ABL1 \% ratio = Not detected |
| 17 | Negative |  | ETV6-RUNX1/ABL1 \% ratio $=$ Not detected |
| 18 | Positive | 0.3400 | ETV6-RUNX1/ABLI \% ratio = 5.8 |
| 19 | Positive | 0.0620 | $E T V 6-R U N X 1 / A B L 1$ \% ratio $=3.0$ |
| 20 | Positive | 0.0090 | ETV6-RUNX1/ABLI \% ratio $=0.7$ |

## 2) Precision

Low-level leukemic samples were tested at least twice and the mean event of leukemic cell was 34, SD 5.66 with CV $16.6 \%$ and another level sample with mean leukemic events 75 with SD 19.80 and CV of $26.4 \%$ within $35 \% \mathrm{CV}$.
3) Linearity or reportable range
$R^{2}$ of the simulated samples (leukemic samples mixed with normal sample) at least three levels were $>0.95$. The linearity was validated from 0.001 to $85.0 \%$.




## Linearity 2 at low level


4) Limit of detection and lower limit of quantitation

Using bone marrow samples from three non-leukemic samples, LOB and LOD were assessed and resulted in LOB of 8 events, $0.000132 \%$, and LOD of 10 events, $0.000169 \%$. LLOQ was assigned as a level at $<35 \% \mathrm{CV}$. Since the level of MRD events with 25 did not pass CV criteria, MRD events with mean 75 , and 80.5 passed the criteria. The MRD events with highest value was 100 , thus 100 events were set as the LLOQ value.

| sample 1 | Total <br> nucleated <br> cell events | 3984652 | 3906414 | Mean | SD | CV | CV <35\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | MRD event | 12 | 38 | 25 | 18.38478 | 73.53911 | Not passed |
|  | MRD \% | 0.000301 | 0.000973 |  |  |  |  |
| sample 2 | Total <br> nucleated <br> cell events | 4301160 | 4287261 |  |  |  |  |
|  | MRD event | 61 | 89 | 75 | 19.79899 | 26.39865 | OK |
|  | MRD\% | 0.001418 | 0.002076 |  |  |  |  |
| sample 3 | Total <br> nucleated <br> cell events | 4314412 | 4309081 |  |  |  |  |
|  | MRD event | 61 | 100 | 80.5 | 27.57716 | 34.25735 | OK |
|  | MRD\% | 0.001414 | 0.002321 |  |  |  |  |

## References

1. Clinical and Laboratory Standards Institute (CLSI). Validation of Assays performed by flow cytometry. $1^{\text {st }}$ ed. CLSI guideline H62. Clinical and Laboratory Standards Institute, USA, 2021.

Supplementary Table 1. Details of the discordant cases.

| Case | Patient | MFC-MRD | MFC-MRD (\%) | NGS-MRD | NGS-MRD (\%) | Major MRD clone | Other molecular studies |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 1 | Negative |  | Positive | 0.0050 | V3-J4 |  |
| 2 | 2 | Negative |  | Positive | 0.0034 | V4-J3 |  |
| 3 | 3 | Negative |  | Positive | 0.0022 | V1-J6 |  |
| 4 | 4 | Negative |  | Positive | 0.0023 | V3-J4 |  |
| 5 | 5 | Negative |  | Positive | 0.0037 | V3-J4 |  |
| 6 | 6 | Negative |  | Positive | 0.0263 | V4-J5 |  |
| 7 | 7 | Negative |  | Positive | 0.0229 | V3-J2 |  |
| 8 | 8 | Negative |  | Positive | 0.0012 | V1-J2 |  |
| 9 | 9 | Negative |  | Positive | 0.5250 | V3-none | $B C R:: A B L 1$ detected |
| 10 | 10 | Negative |  | Positive | 0.0005 | V1-J4 |  |
| 11 | 11 | Negative |  | Positive | 0.0054 | V3-J6 | $B C R:: A B L 1$ not detected |
| 12 | 12 | Negative |  | Positive | 0.0029 | V4-J4 |  |
| 13 | 13 | Negative |  | Positive | 0.0052 | V3-J6 |  |
| 14 | 13 | Negative |  | Positive | 0.0074 | V3-J6 |  |
| 15 | 13 | Negative |  | Positive | 0.0080 | V3-J6 |  |
| 16 | 14 | Negative |  | Positive | 0.0041 | V2D-DEL | ETV6::RUNX1 Not detected |
| 17 | 14 | Negative |  | Positive | 0.0018 | V2D-DEL | ETV6::RUNX1 Not detected |
| 18 | 14 | Negative |  | Positive | 0.0026 | V2D-DEL | ETV6::RUNX1 Not detected |
| 19 | 15 | Negative |  | Positive | 0.0027 | V1-J4 |  |
| 20 | 16 | Negative |  | Positive | 0.0122 | V3-J4 |  |
| 21 | 17 | Negative |  | Positive | 0.0009 | V2-IGKDEL | $B C R:: A B L 1$ detected |
| 22 | 17 | Negative |  | Positive | 0.0001 | V2-IGKDEL | $B C R:: A B L 1$ not detected |
| 23 | 18 | Negative |  | Positive | 0.0057 | V6-J4 | $B C R:: A B L 1$ detected |
| 24 | 19 | Negative |  | Positive | 0.0035 | V1-J4 | ETV6::RUNX1 Not detected |
| 25 | 20 | Negative |  | Positive | 0.0001 | V4_39-J6 | $B C R:: A B L 1$ detected |


| 26 | 21 | Positive | 0.0025 | Negative | V1-J5 |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 27 | 22 | Positive | 0.0026 | Negative | V1-J4 |  |
| 28 | 23 | Positive | 0.0089 | Negative | V3-J6 | $B C R:: A B L 1$ detected |

